Idiopathic Pulmonary Fibrosis

• FDA approval · 2018-11-09
  FDA Approved: OFEV — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for OFEV (nintedanib) submitted by Boehringer Ingelheim Pharmaceuticals, Inc., indicating an app…

• FDA approval · 2017-01-11
  FDA Approved: ESBRIET — Original Application (Genentech, Inc.)

  FDA approves Esbriet (pirfenidone) from Genentech in an Original Application for the treatment of idiopathic pulmonary fibrosis.

• FDA approval · 2016-02-04
  FDA Approved: OFEV — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

  FDA approved a supplemental application for OFEV (nintedanib) filed by Boehringer Ingelheim Pharmaceuticals, Inc., expanding its approved us…

• FDA approval · 2014-10-15
  FDA Approved: OFEV — Original Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

  The FDA approved OFEV (nintedanib) as the original application for the treatment of idiopathic pulmonary fibrosis. This marked the initial r…